Sinopharm wins approval for inhaled Omicron antibody trials

Chinese drugmaker Sinopharm said on Monday it has obtained approval to conduct clinical trials of an inhaled monoclonal antibody against the novel coronavirus, a potentially significant weapon against the dominant Omicron variant.

Related Keywords

Hangzhou , Zhejiang , China , Chinese , , National Medical Products Administration On , China National Biotech Group , Battle Against Novel , National Biotech Group , National Medical Products Administration ,